According to Future Market Insights research, during the projected period, the global Intranasal Corticosteroids Market is expected to grow at a CAGR of 5.0%. The market value is projected to increase from USD 6.8 Billion in 2023 to USD 11.2 Billion by 2033. The intranasal corticosteroids market was valued at USD 6.5 Billion at the end of 2022 and is anticipated to exhibit Y-o-Y growth of 4.8% in 2023.
Market Outlook:
| Data Points | Market Insights |
|---|---|
| Market Value 2022 | USD 6.5 Billion |
| Market Value 2023 | USD 6.8 Billion |
| Market Value 2033 | USD 11.2 Billion |
| CAGR 2023 to 2033 | 5.0% |
| Market Share of Top 5 Countries | 54.1% |
| Key Market Players | Merck & co., GlaxoSmithKline, AstraZeneca, Sanofi, Perrigo Co., Teva Pharmaceutical Industries, Glenmark Pharmaceuticals, Mylan, Novartis, Pfizer, Pharmascience |
Nasal steroid sprays are a type of medication that delivers corticosteroids directly into the nasal passages to alleviate symptoms associated with nasal allergies, including sneezing and a runny nose.
These sprays offer effective relief from hay fever and other nasal allergies, often serving as a viable alternative to oral allergy medications. It usually takes a few days of consistent use for the sprays to take effect. To maintain ongoing relief, it is important to use them daily throughout the allergy season.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The market value for intranasal corticosteroids expanded at a CAGR of close to 4.9% between 2017 and 2022. The intranasal corticosteroids market is around 32.4% of the overall USD 20.2 Billion global allergy treatment market in 2022.
The global market for intranasal corticosteroids experienced growth over past few decades driven by the increased prevalence of condition like allergic rhinitis and Chronic Obstructive Pulmonary Disease (COPD).
This increased prevalence has impacted infants, young children, and the elderly population suffering from these conditions. Most corticosteroids used are for treatment of seasonal allergic rhinitis caused due to aeroallergen.
Companies have been constantly working towards development of products to treat allergy related conditions which are effective yet cost-efficient.
This particular nasal spray has the capability to alleviate three common symptoms associated with allergic rhinitis, namely sneezing, nasal discharge, and nasal congestion.
As a result of these advantageous qualities, there has been a notable rise in the demand for intranasal corticosteroids.
Using a corticosteroid spray consistently on a daily basis is the most effective way to experience its benefits. To reduce symptoms during pollen season, it is recommended to start using the spray at the beginning of the season.
It is worth mentioning that nasal corticosteroid sprays are generally safe for adults, and there are specific types that are also safe for children aged 2 and older. Pregnant women can also use corticosteroid sprays safely, but it is important for them to consult with their healthcare provider to choose the options with the best safety record during pregnancy.
This ensures that a wider population can benefit from the use of intranasal corticosteroids worldwide.
Prominent companies are actively pursuing acquisitions and expanding their operations to strengthen their product offerings and reach a broader customer base.
The above factors are likely to drive the global market in next few years.
Principal Consultant
Although all intranasal corticosteroids (INCSs) used for treating allergic rhinitis (AR) are generally considered safe and effective, variations in potency, molecular structure, and physicochemical and pharmacokinetic properties can lead to differences in their clinical effectiveness and safety profiles.
Some common side effects associated with intranasal corticosteroids include headache, nausea and vomiting, drowsiness, light-headedness, palpitations, loss of taste, wheezing, nosebleeds (epistaxis), nasal ulceration, irritation of the nose and throat (nasopharyngeal irritation), musculoskeletal pain, immunosuppression, and an increased risk of infections.
However, patients with low incomes, especially in developing countries, find it difficult to afford inhaled and intranasal corticosteroids. As a result, they often have no choice but to rely on less effective oral medications.
The USA leads the North America market contributing around USD 1.9 Billion in 2022.
Prevalence of allergies in the United States is relatively high, with millions of individuals suffering from seasonal and perennial allergies each year. The accessibility and availability of intranasal corticosteroid medications in the USA market contribute to their increased usage.
Moreover, healthcare professionals in the USA are well-informed about the benefits of intranasal corticosteroids and frequently prescribe them to patients who require allergy relief.
In the United States, there are currently nine branded Intranasal Corticosteroid products available. Among them, Nasacort Allergy 24HR (triamcinolone acetonide) and Flonase Allergy Relief (fluticasone propionate) are available over the counter.
Drug manufacturers are actively working to maximize the therapeutic effects of corticosteroid therapy while minimizing potential systemic adverse effects and improving patient adherence.
Overall, these factors contribute to the higher usage of intranasal corticosteroids in the United States.
In 2022, the China held a dominant share of in the East Asia market and contributed around USD 466.0 Million.
The increasing urbanization and adoption of Westernized lifestyles in developing countries, along with rapid economic growth, have contributed to a rising trend of AR in recent decades. The prevalence of AR in China varies widely. Additionally, the impact of air pollution and climate change on respiratory disorders cannot be disregarded.
India holds nearly 6.7% market share in the global market in 2022. India is the lucrative market region in the South Asian market in revenue terms in 2022.
Indian subcontinent has witnessed a rise in allergic rhinitis and asthma cases over the past few decades.
India, on a global scale, faces one of the significant levels of air pollution, primarily caused by fossil fuels, vehicular emissions, and biomass. Additionally, the use of incense, mosquito coils, and dhoop sticks contributes significantly to indoor pollution. All these factors cumulatively is expected to boost the global market for intranasal corticosteroids market in India.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
The global market for intranasal sprays reached a substantial value of USD 4.7 Billion in 2022.
Nasal sprays are liquid medications that are administered by spraying them into the nose. They are specifically designed to alleviate discomfort and congestion caused by allergies. Nasal sprays come in two types of containers: pressurized canisters and pump bottles.
Some commonly known examples of nasal sprays include Naselin Nasal Spray, Astelin, Astepro, Nazal Spray, Vicks Ultra Fine Mist, Otrivin Spray, and Sinarest Spray.
During year 2022, Allergic rhinitis accounts for around 58.1% of the global market share. Intranasal corticosteroid (INCS) therapy is considered the preferred treatment option for allergic rhinitis (AR) as it effectively inhibits the degranulation of mast cells.
While these sprays are generally safe to use, they are not typically recommended as the first-line therapy for allergic rhinitis due to their lower effectiveness in relieving symptoms compared to antihistamines or intranasal corticosteroids. Additionally, their dosing schedule of three or four times daily can be inconvenient.
Fluticasone Propionate accounts for 25.3% of the global market share in 2022.
Fluticasone Propionate helps reduce airway inflammation, thus improving breathing followed by reduced symptoms like coughing, shortness of breath and wheezing. It is also available as a nasal spray for the treatment of allergic rhinitis.
Fluticasone Propionate is considered an effective and commonly prescribed medication for respiratory conditions, and it is available in various brand names and forms. However, it should only be used under medical supervision and as prescribed by a healthcare professional.
Retail pharmacies captured a significant market share of around 31.7% in 2022. Retail pharmacies have established a strong presence with numerous conveniently located branches in various neighbourhoods and communities.
This widespread accessibility ensures that customers can easily purchase nasal corticosteroids without the need to travel long distances or wait for delivery.
Secondly, these pharmacies are staffed with well-trained pharmacists who are capable of providing valuable guidance and recommendations to customers regarding the use of nasal corticosteroids. This personalized advice instils confidence in customers and empowers them to make informed decisions about their healthcare.
In the market for intranasal corticosteroids, key players are implementing various strategies to increase their sales and generate revenue.
Bayer Healthcare LLC received FDA approval on June 17, 2021, for the nonprescription use of Astepro. This approval allows allergy sufferers to use the nasal sprays without the assistance of a healthcare provider when needed.
Similarly, recent developments related to the company’s manufacturing the Intranasal Corticosteroids have been tracked by the team at Future Market Insights, which are available in the full report.
| Attribute | Details |
|---|---|
| Forecast Period | 2023 to 2033 |
| Historical Data Available for | 2017 to 2022 |
| Market Analysis | USD Million for Value |
| Key Regions Covered | North America; Latin America; Europe; South Asia; East Asia; Oceania; and MEA |
| Key Countries Covered | USA, Canada, Brazil, Mexico, Argentina, Germany, Italy, France, UK, Spain, BENELUX, Russia, India, Thailand, China, Indonesia, Malaysia, Japan, South Korea, Australia, New Zealand, GCC countries, Türkiye, Northern Africa and South Africa. |
| Key Market Segments Covered | Indication, Dosage Form, Drug, Distribution Channel, Region |
| Key Companies Profiled | Merck & co.; GlaxoSmithKline; AstraZeneca; Sanofi; Perrigo Co.; Teva Pharmaceutical Industries; Glenmark Pharmaceuticals; Mylan; Novartis; Pfizer; Pharmascience |
| Report Coverage | Market Forecast, Competition Intelligence, DROT Analysis, Market Dynamics and Challenges, Strategic Growth Initiatives |
| Pricing | Available upon Request |
The primary consumer for Intranasal Corticosteroids is the allergy and asthma industry.
The United States is poised to stay attractive, projecting a USD 1.5 billion market by 2033.
The market is estimated to secure a valuation of USD 6.8 billion in 2023.
The market is estimated to reach USD 11.2 billion by 2033.
The allergy and asthma sector holds high revenue potential.
1. Executive Summary 2. Market Overview 3. Key Market Trends 4. Value Added Insights 5. Market Background 6. Global Market Demand (in Value or Size in USD Million) Analysis 2017 to 2022 and Forecast, 2023 to 2033 7. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, by Drug 7.1. Fluticasone Propionate 7.2. Budesonide 7.3. Beclomethasone Dipropionate 7.4. Mometasone Furoate 7.5. Triamcinolone Acetonide 7.6. Ciclesonide 7.7. Flunisolide 7.8. Tixocortol 8. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Indication 8.1. Allergic Rhinitis (AR) 8.1.1. Seasonal AR 8.1.2. Perennial AR 8.2. Non-Allergic Rhinitis (NAR) 8.2.1. Infectious NAR 8.2.2. Vasomotor NAR 8.2.3. Atrophic NAR 9. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Dosage Form 9.1. Intranasal Drops 9.2. Intranasal Sprays 10. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Distribution Channel 10.1. Hospitals 10.2. Retail Pharmacies 10.3. Drug Stores 10.4. Online Pharmacies 11. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, by Region 11.1. North America 11.2. Latin America 11.3. Europe 11.4. East Asia 11.5. South Asia 11.6. Oceania 11.7. Middle East and Africa 12. North America Market Analysis 2017 to 2022 and Forecast 2023 to 2033 13. Latin America Market Analysis 2017 to 2022 and Forecast 2023 to 2033 14. Europe Market Analysis 2017 to 2022 and Forecast 2023 to 2033 15. South Asia Market Analysis 2017 to 2022 and Forecast 2023 to 2033 16. East Asia Market Analysis 2017 to 2022 and Forecast 2023 to 2033 17. Oceania Market Analysis 2017 to 2022 and Forecast 2023 to 2033 18. Middle East and Africa Market Analysis 2017 to 2022 and Forecast 2023 to 2033 19. Market Structure Analysis 20. Competition Analysis 20.1. GlaxoSmithKline 20.2. AstraZeneca 20.3. Sanofi 20.4. Perrigo Co. 20.5. Teva Pharmaceutical Industries 20.6. Glenmark Pharmaceuticals 20.7. Mylan 20.8. Novartis 20.9. Pfizer 20.10. Pharmascience 21. Assumptions and Acronyms Used 22. Research Methodology
Explore Healthcare Insights
View Reports
Intranasal Corticosteroids Market
